Jasper Therapeutics(JSPR) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., November 7, 2024 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal ...